Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Reorganizes to Focus on Pharmacogenomics, Metabolomics

NEW YORK, Jan. 20 (GenomeWeb News) - Clinical Data is consolidating its operations into two divisions in an attempt to focus efforts on its pharmacogenomics and metabolomics programs, the company announced today.

 

The new businesses will be called Clinical Data Molecular and Vital Diagnostics. Making up Clinical Data Molecular will be the operations acquired by the company in 2005: Genaissance (together with its Lark Technologies assets) and Icoria. The Vital Diagnostics division will consolidate the company's previously owned subsidiaries.

 

Israel Stein, in a statement. "Our emphasis will be to expand our menus of molecular services available to physicians, payors, pharmaceutical and biotechnology companies, and academic research organizations," he said.

 

The company said that the businesses comprising the Clinical Data Molecular unit generated $33 million for the 12 months ended Sept. 30. Vital Diagnostics revenues were about $53 million for that period.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more